Purpose: The effects of pan-histone deacetylase (HDAC) inhibitors on cancer cells have shown that HDACs are involved in fundamental tumor biological processes such as cell cycle control, differentiation, and apoptosis. However, because of the unselective nature of these compounds, little is known about the contribution of individual HDAC family members to tumorigenesis and progression. The purpose of this study was to evaluate the role of individual HDACs in neuroblastoma tumorigenesis. Experimental Design: We have investigated the mRNA expression of all HDAC1-11 family members in a large cohort of primary neuroblastoma samples covering the full spectrum of the disease. HDACs associated with disease stage and survival were subsequently func...
BACKGROUND: Histone deacetylase inhibitors (HDACi) are a new class of promising anti-tumour agent in...
Objective: MS-275, a phase trialed histone deacetylase inhibitor will be characterized for its abil...
Objective: MS-275, a phase trialed histone deacetylase inhibitor will be characterized for its abil...
PURPOSE: The effects of pan-histone deacetylase (HDAC) inhibitors on cancer cells have shown that HD...
Histone deacetylases (HDACs) are an emerging class of novel anti-cancer drug targets. Recently, stud...
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic ...
SummaryWhile cytotoxic chemotherapy remains the hallmark of cancer treatment, intensive regimens fal...
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic ...
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic ...
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic ...
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic ...
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic ...
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic ...
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic ...
The number of long-term survivors of high-risk neuroblastoma remains discouraging, with 10-year surv...
BACKGROUND: Histone deacetylase inhibitors (HDACi) are a new class of promising anti-tumour agent in...
Objective: MS-275, a phase trialed histone deacetylase inhibitor will be characterized for its abil...
Objective: MS-275, a phase trialed histone deacetylase inhibitor will be characterized for its abil...
PURPOSE: The effects of pan-histone deacetylase (HDAC) inhibitors on cancer cells have shown that HD...
Histone deacetylases (HDACs) are an emerging class of novel anti-cancer drug targets. Recently, stud...
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic ...
SummaryWhile cytotoxic chemotherapy remains the hallmark of cancer treatment, intensive regimens fal...
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic ...
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic ...
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic ...
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic ...
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic ...
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic ...
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic ...
The number of long-term survivors of high-risk neuroblastoma remains discouraging, with 10-year surv...
BACKGROUND: Histone deacetylase inhibitors (HDACi) are a new class of promising anti-tumour agent in...
Objective: MS-275, a phase trialed histone deacetylase inhibitor will be characterized for its abil...
Objective: MS-275, a phase trialed histone deacetylase inhibitor will be characterized for its abil...